"Blast and cruise" is a bodybuilding strategy where someone alternates between high-dose testosterone phases (the "blast") and lower TRT-level doses (the "cruise"). It is not a medically supervised protocol, and most physicians and TRT clinics will not prescribe it due to documented cardiovascular, hematological, and hormonal risks. For foundational TRT information, see our TRT Benefits: What Testosterone Therapy Actually Does.
Key Takeaway
Blast and cruise cycling involves supraphysiological testosterone doses (300-500mg/week) followed by TRT-level doses (100-200mg/week), repeated indefinitely without post-cycle therapy. Research shows this pattern raises hematocrit, damages lipid profiles, and causes reversible but measurable cardiac hypertrophy. This is not a protocol FormBlends offers or endorses.
What Does "Blast and Cruise" Mean in Bodybuilding?
The term comes from underground bodybuilding culture. A "blast" phase means running testosterone at 300-500mg per week (sometimes higher, sometimes stacked with other anabolic compounds) for 8-16 weeks. A "cruise" phase means dropping back down to a standard TRT dose of 100-200mg per week. The cycle repeats indefinitely.
The key difference between blast and cruise and traditional steroid cycling is the absence of post-cycle therapy (PCT). In a traditional cycle, a user runs supraphysiological doses for a set period, then stops entirely and uses drugs like clomiphene or tamoxifen to restart natural testosterone production. With blast and cruise, the user never comes off testosterone completely. They just oscillate between high and low doses.
The logic, from the bodybuilding perspective, is simple: PCT is miserable, recovery of natural production is uncertain, and staying on a cruise dose means you keep your gains and feel normal between blasts. Whether this actually reduces total health risk compared to traditional cycling is debatable, and no controlled studies have compared the two approaches directly. The The TOT Protocol: What Testosterone Optimization Therapy Actually Means offers another structured approach.
How Does Blast and Cruise Differ from Standard TRT?
Standard TRT aims to restore testosterone to normal physiological levels, typically targeting 500-900 ng/dL on trough readings. The dose stays consistent, usually 100-200mg of testosterone cypionate or enanthate per week. The goal is symptom relief and maintaining levels within the reference range.
Blast and cruise is fundamentally different in intent. The blast phase pushes testosterone well above the physiological ceiling. At 500mg/week, total testosterone levels can exceed 2,000-3,000 ng/dL, which is 3-5 times the upper limit of normal. This is the dose range where anabolic effects on muscle protein synthesis become significant, but so do side effects (Ory et al., 2022). All TRT approaches carry risks; review our TRT Side Effects: What to Expect and How to Manage Them guide.
During the cruise phase, levels return to a normal TRT range. But the repeated cycling between extremes creates a pattern of hormonal instability that no clinical protocol replicates. Estradiol, hematocrit, lipids, and blood pressure all swing with each transition.
What Happens to Bloodwork During a Blast Phase?
The hematological and metabolic changes during supraphysiological testosterone use are well-documented. What clinicians typically observe during blast phases:
Check if TRT is right for you
Take a free 2-minute assessment to see if testosterone replacement therapy could help restore your energy, mood, and vitality.
Start Free Assessment →| Marker | Normal TRT Range | Typical Blast Phase | Clinical Concern |
|---|---|---|---|
| Hematocrit | 42-50% | 52-58%+ | Polycythemia, blood viscosity |
| Estradiol | 20-40 pg/mL | 60-120+ pg/mL | Gynecomastia, water retention |
| HDL cholesterol | 40-60 mg/dL | 20-35 mg/dL | Increased cardiovascular risk |
| LDL cholesterol | < 130 mg/dL | Often elevated | Atherogenic lipid profile |
| LH / FSH | Suppressed on TRT | Fully suppressed | Infertility, testicular atrophy |
| ALT / AST | Normal | Mildly elevated | Hepatic stress (especially with orals) |
Polycythemia is the most immediate clinical concern. A 2022 study in The Journal of Urology found that men who developed polycythemia (hematocrit above 52%) while on testosterone therapy had a 35% higher odds of major adverse cardiovascular events and venous thromboembolism compared to men with normal hematocrit levels (PMID: 35050717). At blast-level doses, erythrocytosis rates with intramuscular testosterone injections can reach 40% (PMC5690890).
What Are the Cardiovascular Risks of Blast and Cruise?
The cardiac effects of supraphysiological testosterone are distinct from those of standard TRT. The 2023 TRAVERSE trial showed that properly managed TRT does not significantly increase cardiovascular risk, with major adverse cardiac events occurring in 7.0% of the testosterone group vs. 7.3% of placebo (PMC12670475). But the TRAVERSE trial used therapeutic doses. Blast-level doses are a different situation entirely.
The HAARLEM study examined bodybuilders using supraphysiological androgen doses and found measurable increases in left ventricular mass, a roughly 5% reduction in left ventricular ejection fraction, and increased cardiac stiffness during use. These changes correlated with weekly dose: higher doses produced more cardiac remodeling. After discontinuation (median 8 months), most parameters returned to baseline (PMC9580689).
The reversibility finding is somewhat reassuring for short-term use. But long-term AAS users show persistent left ventricular hypertrophy even after stopping, suggesting that repeated blast cycles may cause cumulative damage that eventually becomes permanent (Baggish et al., 2010).
Why Won't Most Doctors Supervise Blast and Cruise?
The reasons are straightforward. Prescribing supraphysiological testosterone doses for muscle gain is not within FDA-approved indications. It exposes the prescriber to malpractice liability. And the risk-benefit ratio, from a medical standpoint, does not onlyify it.
Testosterone is FDA-approved for the treatment of hypogonadism, meaning clinically low testosterone with associated symptoms. The approved dose range targets physiological restoration, not performance enhancement. A doctor who prescribes 500mg/week of testosterone cypionate for bodybuilding purposes is practicing outside accepted medical standards.
Some anti-aging and "optimization" clinics will prescribe higher-end TRT doses (up to 200mg/week), but even these clinics generally draw the line well below blast-level dosing. The monitoring burden alone, with frequent bloodwork, echocardiograms, and potential need for therapeutic phlebotomy, makes supervised blast and cruise impractical in most clinical settings.
What About Harm Reduction?
Harm reduction is a practical reality in this space. People who choose to blast and cruise despite the risks can take steps to reduce (not eliminate) potential damage:
- Regular bloodwork: Complete blood count, comprehensive metabolic panel, lipid panel, and sensitive estradiol every 8-12 weeks, and more often during blast phases.
- Hematocrit management: Therapeutic phlebotomy or blood donation if hematocrit exceeds 52%. Some clinicians recommend naringin or grapefruit extract, though evidence for these is weak.
- Cardiovascular monitoring: Annual echocardiogram, regular blood pressure checks, and coronary artery calcium scoring for long-term users.
- Lipid management: Omega-3 supplementation, cardiovascular exercise, and potentially statin therapy if LDL remains elevated.
- Estrogen management: Aromatase inhibitors at the lowest effective dose if estradiol becomes symptomatic. Over-suppression of estradiol carries its own risks (joint pain, lipid worsening, bone density loss).
- Fertility preservation: HCG at 500-1000 IU 2-3 times per week to maintain intratesticular testosterone and some degree of spermatogenesis.
These measures do not make blast and cruise safe. They make it less dangerous. The distinction matters. No amount of bloodwork monitoring eliminates the risk of cardiac remodeling from repeated supraphysiological testosterone exposure. Fertility preservation requires the Testosterone + HCG Stack: Maintaining Fertility on TRT approach.
How Does Blast and Cruise Compare to Standard TRT and Traditional Cycling?
| Factor | Standard TRT | Traditional Cycling + PCT | Blast and Cruise |
|---|---|---|---|
| Dose range | 100-200mg/week | 300-500mg/week on, 0 off | 300-500mg blast, 100-200mg cruise |
| Time off testosterone | None (continuous) | Yes (PCT period) | None (continuous) |
| Natural production recovery | Not expected | Attempted with PCT | Abandoned |
| Medical supervision | Standard of care | Rarely supervised | Rarely supervised |
| Cardiac risk | Minimal (TRAVERSE data) | Elevated during cycle | Elevated, potentially cumulative |
| Fertility impact | Suppressed (reversible with HCG) | Suppressed, recovery attempted | Chronically suppressed |
Is There Any Legitimate Medical Use for Dose Cycling?
No mainstream medical guideline recommends cycling testosterone doses between supraphysiological and physiological levels. Some researchers have explored pulsatile testosterone administration, but these protocols use doses within or near the physiological range and bear no resemblance to blast and cruise.
The closest clinical parallel might be seasonal dose adjustments some clinicians make based on SHBG fluctuations or symptom changes. But these are minor tweaks within the therapeutic range, not 2-3x swings in dose.
If you are considering testosterone replacement therapy, the evidence supports stable, physiological dosing with regular monitoring. That approach has decades of safety data behind it. Blast and cruise does not.
Frequently Asked Questions
Is blast and cruise safer than traditional steroid cycling with PCT?
There is no clinical evidence that either approach is safer than the other. Blast and cruise avoids the hormonal crash of PCT but means you never give your cardiovascular system and HPTA a full break from exogenous hormones. Traditional cycling allows partial recovery but involves the risks of PCT drugs and repeated hormonal disruption.
What hematocrit level becomes dangerous during a blast?
European guidelines consider hematocrit above 54% a contraindication to continued testosterone therapy. American guidelines use 50% as the threshold. During blast phases, hematocrit above 52% warrants immediate dose reduction or therapeutic phlebotomy to reduce stroke and clotting risk.
Can blast and cruise cause permanent heart damage?
Short-term supraphysiological use causes reversible cardiac changes (the HAARLEM study showed recovery within 8 months). But long-term or repeated use is associated with persistent left ventricular hypertrophy and reduced ejection fraction that may not fully reverse.
Will a TRT clinic prescribe blast-level doses?
Legitimate TRT clinics will not prescribe supraphysiological doses for bodybuilding purposes. This falls outside FDA-approved indications and standard medical practice. Clinics that do prescribe these doses operate in a legal and ethical gray area.
Does FormBlends offer blast and cruise protocols?
No. FormBlends provides standard TRT protocols aimed at restoring testosterone to physiological levels under medical supervision. Supraphysiological dosing is not part of the FormBlends treatment model.
How often should bloodwork be done during a blast phase?
Harm reduction guidelines suggest bloodwork every 4-6 weeks during blast phases, including CBC with hematocrit, a lipid panel, liver enzymes, and sensitive estradiol. This is more frequent than the every-3-to-6-month schedule typical of standard TRT monitoring.
Can you maintain fertility while blast and cruising?
Fertility is significantly compromised. Exogenous testosterone suppresses LH and FSH, which shuts down sperm production. HCG can help maintain some spermatogenesis, but at supraphysiological testosterone levels, the suppressive signal is stronger and fertility preservation is less reliable than during standard TRT.
Medical References
- Ory J, et al. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. J Urol. 2022;207(6):1289-1296. PMID: 35050717
- Ohlander SJ, et al. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018;6(1):77-85. PMC5690890
- de Ronde W, et al. Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction: Echocardiography Results of the HAARLEM Study. Front Reprod Health. 2021;3:732318. PMC9580689
- Baggish AL, et al. Long-Term Anabolic-Androgenic Steroid Use Is Associated With Left Ventricular Dysfunction. Circ Heart Fail. 2010;3(4):472-476. DOI: 10.1161/CIRCHEARTFAILURE.109.931063
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107-117. PMID: 37334136
- Budoff MJ, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708-716. PMID: 28241355
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any medication or protocol. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10